34 completed. 34 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 34 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 3 |
Follow Hypopigmentation: new trials by email Literature Review of Hypopigmentation trials Research Report on Hypopigmentation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo MH004 Ointment, Vehicle Ointment - Vitiligo | Phase 2 | Completed | Minghui Pharmaceutical (Hangzhou) Ltd | 156 | 2024-03-26 | 2026-06-04 |
| Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas Ruxolitinib Topical, Placebo - Vitiligo | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 20 | 2023-09-05 | 2025-01-20 |
| Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo Methotrexate, Placebos - Vitiligo | Phase 2 | Completed | University Hospital, Bordeaux | 32 | 2023-05-23 | 2026-05-22 |
| A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo Ruxolitinib Cream - Nonsegmental Vitiligo With Genital Involvement | Phase 2 | Completed | Incyte Corporation | 49 | 2023-04-11 | 2026-03-20 |
| Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy - Vitiligo | Phase 2 | Completed | University of Colorado, Denver | 32 | 2022-09-07 | 2024-06-12 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo Ruxolitinib 1.5% cream, NB-UVB phototherapy - Vitiligo | Phase 2 | Completed | Incyte Corporation | 55 | 2022-05-05 | 2025-02-20 |
| Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo. Latanoprost 0.005% Ophthalmic Solution, 5Fluorouracil - Vitiligo | Phase 2 / Phase 3 | Completed | South Valley University | 40 | 2022-03-15 | 2023-07-11 |
| Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo Baricitinib Oral Product, Placebo - Vitiligo | Phase 2 | Completed | University Hospital, Bordeaux | 49 | 2021-07-16 | 2026-06-12 |
| Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Upadacitinib, Placebo - Non-Segmental Vitiligo | Phase 2 | Completed | AbbVie | 185 | 2021-06-30 | 2024-10-08 |
| A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) Ruxolitinib cream, Vehicle Cream - Vitiligo | Phase 2 | Completed | Incyte Corporation | 60 | 2021-06-23 | 2025-08-05 |
| Evaluation of AMG 714 for Vitiligo AMG 714, Placebo, nbUVB phototherapy - Vitiligo | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2020-12-11 | 2026-04-21 |
| Tofacitinib for Immune Skin Conditions in Down Syndrome Tofacitinib - Down Syndrome, Alopecia Areata | Phase 2 | Completed | University of Colorado, Denver | 47 | 2020-10-21 | 2025-12-11 |
| Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Cerdulatinib 0.37% gel, Vehicle gel - Vitiligo | Phase 2 | Completed | Dermavant Sciences GmbH | 33 | 2019-09-27 | 2020-11-24 |
| A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo ATI-50002 topical solution - Vitiligo | Phase 2 | Completed | Aclaris Therapeutics, Inc. | 34 | 2018-03-19 | 2020-11-30 |
| A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Ruxolitinib cream, Vehicle cream - Vitiligo | Phase 2 | Completed | Incyte Corporation | 157 | 2017-06-07 | 2022-11-17 |
| Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Apremilast, NB-UVB phototherapy - Vitiligo | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 23 | 2017-04-14 | 2019-08-28 |
| Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO Apremilast, Placebo - Vitiligo | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 80 | 2017-03-20 | 2026-03-24 |
| Topical Ruxolitinib for the Treatment of Vitiligo Ruxolitinib 1.5% Phosphate Cream - Vitiligo | Phase 2 | Completed | Tufts Medical Center | 11 | 2016-01-01 | 2020-08-31 |
| Atorvastatin in Active Vitiligo Atorvastatin, UVB - Vitiligo | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 28 | 2015-05-01 | 2026-03-24 |
| Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. ponatinib hydrochloride, laboratory biomarker analysis - Malignant Neoplasm | Phase 2 | Completed | Sameek Roychowdhury | 22 | 2015-02-24 | 2025-03-24 |
Showing 20 of 34. Sign in to see all of them.
Vitiligo (28) · Albinism (3) · Piebaldism (3) · Skin Diseases (2) · Albinism, Oculocutaneous (1) · Alopecia Areata (1) · Autoimmune Diseases (1) · Dermatitis, Atopic (1) · Down Syndrome (1) · Eczema (1) · Gastrointestinal Stromal Tumors (1) · Hermanski-Pudlak Syndrome (1) · Hidradenitis Suppurativa (1) · Inflammation (1)
Skin and Connective Tissue Diseases (34) · Pigmentation Disorders (33) · Skin Diseases (32) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Skin Diseases, Genetic (7) · Amino Acid Metabolism, Inborn Errors (6) · Eye Diseases, Hereditary (6) · Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Metabolism, Inborn Errors (5) · Pathological Conditions, Signs and Symptoms (4) · Albinism (3) · Eye Diseases (3)
ruxolitinib (4) · Imatinib Mesylate (2) · afamelanotide (2) · apremilast (2) · 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide (1) · AMG-714 (1) · Atorvastatin (1) · Cell- and Tissue-Based Therapy (1) · Etanercept (1) · Fluorouracil (1) · Gels (1) · Lasers, Gas (1) · Latanoprost (1) · Levodopa (1) · Methotrexate (1)
Centre Hospitalier Universitaire de Nice (6) · Incyte Corporation (4) · Clinuvel Pharmaceuticals Limited (2) · University Hospital, Bordeaux (2) · University of Colorado, Denver (2) · AbbVie (1) · Aclaris Therapeutics, Inc. (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Dermavant Sciences GmbH (1) · Icahn School of Medicine at Mount Sinai (1) · John Harris (1) · Minghui Pharmaceutical (Hangzhou) Ltd (1) · National Eye Institute (NEI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1)
United States (19) · France (11) · Canada (5) · Australia (1) · Belgium (1) · China (1) · Egypt (1) · Finland (1) · Indonesia (1) · Japan (1) · Spain (1)
Passeron Thierry, PhD (3) · Alice Gottlieb, MD, PhD (1) · Brett A. King, MD, PhD (1) · Brian P Brooks, M.D. (1) · Chuah Sai Yee, Ph (1) · David Rosmarin, MD (1) · Gail Summers, M.D. (1) · Giovanni Leone, MD (1) · Haq Nawaz, MD (1) · Hassan M Ibrahim, professor (1) · Jean-Marie Naeyaert, MD, PhD (1) · Joaquin Espinosa, PhD (1) · John E. Harris, MD, PhD (1)
PMID 25902042, PMID 29617528, PMID 30674731, PMID 32004567, PMID 32653055, PMID 37840766, PMID 38873632, PMID 38946973, PMID 39475960, PMID 39737640, PMID 39841460, PMID 42869214
2009 (1), 2018 (1), 2023 (1), R33AR077495 (1)